Show simple item record

dc.contributor.authorNishio, M
dc.contributor.authorKim, D-W
dc.contributor.authorWu, Y-L
dc.contributor.authorNakagawa, K
dc.contributor.authorSolomon, BJ
dc.contributor.authorShaw, AT
dc.contributor.authorHashigaki, S
dc.contributor.authorOhki, E
dc.contributor.authorUsari, T
dc.contributor.authorPaolini, J
dc.contributor.authorPolli, A
dc.contributor.authorWilner, KD
dc.contributor.authorMok, T
dc.date.accessioned2020-12-21T01:24:46Z
dc.date.available2020-12-21T01:24:46Z
dc.date.issued2018-07-01
dc.identifierpii: crt.2017.280
dc.identifier.citationNishio, M., Kim, D. -W., Wu, Y. -L., Nakagawa, K., Solomon, B. J., Shaw, A. T., Hashigaki, S., Ohki, E., Usari, T., Paolini, J., Polli, A., Wilner, K. D. & Mok, T. (2018). Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. CANCER RESEARCH AND TREATMENT, 50 (3), pp.691-700. https://doi.org/10.4143/crt.2017.280.
dc.identifier.issn1598-2998
dc.identifier.urihttp://hdl.handle.net/11343/256499
dc.description.abstractPurpose: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. Materials and Methods: This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and "as-treated" populations for efficacy and safety endpoints, respectively. Results: In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. Conclusion: These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
dc.languageEnglish
dc.publisherKOREAN CANCER ASSOCIATION
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleCrizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
dc.typeJournal Article
dc.identifier.doi10.4143/crt.2017.280
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleCancer research and treatment : official journal of Korean Cancer Association
melbourne.source.volume50
melbourne.source.issue3
melbourne.source.pages691-700
dc.rights.licenseCC BY-NC
melbourne.elementsid1222028
melbourne.contributor.authorSolomon, Benjamin
dc.identifier.eissn2005-9256
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record